SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:d36a79e0-6ca9-4cd2-a167-fc7a2bd1fef6"
 

Search: onr:"swepub:oai:lup.lub.lu.se:d36a79e0-6ca9-4cd2-a167-fc7a2bd1fef6" > EURO-B.O.S.S. : A E...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma

Ferrari, Stefano (author)
Rizzoli Orthopedic Institute
Bielack, Stefan S. (author)
Klinikum Stuttgart Olgahospital,Oslo university hospital
Smeland, Sigbjørn (author)
Oslo university hospital
show more...
Longhi, Alessandra (author)
Rizzoli Orthopedic Institute
Egerer, Gerlinde (author)
University Hospital Heidelberg
Sundby Hall, Kirsten (author)
Oslo university hospital
Donati, Davide (author)
Rizzoli Orthopedic Institute
Kevric, Matthias (author)
Klinikum Stuttgart Olgahospital
Brosjö, Otte (author)
Karolinska University Hospital
Comandone, Alessandro (author)
Ospedale Humanitas Gradenigo
Werner, Mathias (author)
HELIOS Klinikum Emil von Behring
Monge, Odd (author)
Haukeland University Hospital
Palmerini, Emanuela (author)
Rizzoli Orthopedic Institute
Berdel, Wolfgang E. (author)
University Hospital Münster
Bjerkehagen, Bodil (author)
Oslo university hospital
Paioli, Anna (author)
Rizzoli Orthopedic Institute
Lorenzen, Sylvie (author)
Technical University of Munich
Eriksson, Mikael (author)
Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
Gambarotti, Marco (author)
Rizzoli Orthopedic Institute
Tunn, Per Ulf (author)
HELIOS Klinikum Berlin-Buch
Jebsen, Nina L. (author)
Haukeland University Hospital
Cesari, Marilena (author)
Rizzoli Orthopedic Institute
von Kalle, Thekla (author)
Klinikum Stuttgart Olgahospital
Ferraresi, Virginia (author)
National Cancer Institute Regina Elena
Schwarz, Rudolf (author)
University Medical Center Hamburg-Eppendorf
Bertulli, Rossella (author)
Istituto Nazionale dei Tumori
Kasparek, Anne Katrin (author)
Medical University of Graz
Grignani, Giovanni (author)
Institute for Cancer Research and Treatment, Candiolo
Krasniqi, Fatime (author)
University Hospital Basel
Sorg, Benjamin (author)
Klinikum Stuttgart Olgahospital
Hecker-Nolting, Stefanie (author)
Klinikum Stuttgart Olgahospital
Picci, Piero (author)
Rizzoli Orthopedic Institute
Reichardt, Peter (author)
HELIOS Klinikum Emil von Behring
show less...
 (creator_code:org_t)
2018-04-27
2018
English 7 s.
In: Tumori. - : SAGE Publications. - 0300-8916 .- 2038-2529. ; 104:1, s. 30-36
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • INTRODUCTION: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma.METHODS: Chemotherapy based on doxorubicin, cisplatin, ifosfamide, and methotrexate was suggested, but patients treated with other regimens at the investigators' choice were also eligible for the study.RESULTS: The present report focuses on the subgroup of 218 patients with primary high-grade osteosarcoma. With a median follow-up of 47 months, the 5-year probability of overall survival (OS) was 66% in patients with localized disease and 22% in case of synchronous metastases. The 5-year OS in patients with localized disease was 29% in pelvic tumors, and 70% and 73% for extremity or craniofacial locations, respectively. In primary chemotherapy, tumor necrosis ≥90% was reported in 21% of the patients. There were no toxic deaths; however, hematological toxicity was considerable with 32% of patients experiencing 1 or more episodes of neutropenic fever. The incidence of nephrotoxicity and neurotoxicity (mainly peripheral) was 28% and 24%, respectively. After methotrexate, 23% of patients experienced delayed excretion, in 4 cases with nephrotoxicity.CONCLUSIONS: In patients over 40 years of age with primary high-grade osteosarcoma, an aggressive approach with chemotherapy and surgery can offer the probability of survival similar to that achieved in younger patients. Chemotherapy-related toxicity is significant and generally higher than that reported in younger cohorts of osteosarcoma patients treated with more intensive regimens.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Adult osteosarcoma
Chemotherapy
Chemotherapy-related toxicity
Osteosarcoma

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • Tumori (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view